CERo Therapeutics Announces Completion of First Cohort of Phase 1 Clinical Trial of CER-1236 in AML

Core Insights - CERo Therapeutics has completed the first cohort of its Phase 1 clinical trial for CER-1236, targeting acute myeloid leukemia (AML), with no dose-limiting toxicities observed and cell expansion consistent with preclinical expectations [1][2][4] - The Dose Escalation Safety Committee has approved the initiation of the second cohort, where three new patients will receive an increased starting dosage [2][4] - The company is not currently seeking partnerships or acquisitions, focusing instead on advancing its clinical trial [5] Company Overview - CERo Therapeutics is an innovative immunotherapy company developing next-generation engineered T cell therapeutics for cancer treatment, integrating innate and adaptive immunity [6] - The company’s lead product candidate, CER-1236, is designed to target both hematologic malignancies and solid tumors, utilizing a novel cellular immunotherapy platform [6][7] Clinical Trial Details - The Phase 1/1b study is designed to evaluate the safety and preliminary efficacy of CER-1236 in patients with relapsed/refractory AML or newly diagnosed patients with TP53 mutated MDS/AML [4] - Primary outcome measures include the incidence of adverse events, dose-limiting toxicities, and overall response rates, while secondary measures focus on pharmacokinetics [4]